Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(44)
•••
Comment by Divineincon Feb 06, 2020 11:08am
35 Views
Post# 30651878

RE:RE:RE:CEO VERY CONFIDENT

RE:RE:RE:CEO VERY CONFIDENTPackerfan666 - (2/6/2020 10:53:32 AM)
RE:RE:CEO VERY CONFIDENT
Sloomoo or Jack whoever you are. I asked you to keep my name out of your mouth. You don't know me. I talked to him after any PR. That's not the point though, I tried to tell you all a couple of concerns , I got shot down out your ingnorance, it's over now, so stop talking about me. You only use my name to fit your tired narrative. The fact is , I know more about this company than you ever could, I have more emails, phone records and deep dive digging than you could. I don't mind you saying you don't believe me, we can agree to disagree but I have 350,000 invested. Don't think you know more, that's just ignorant. 

The Troll use your name on stockhouse and Yahoo board!! 

gary
3 days ago
$KLY.V conversation
ALERT !!! ALERT!! CEO IS NOT CONFIDENT. MAJOR LONG INVESTOR (packerfan) WITH $350K INVESTED STATES “spoke to Rob about 2 months ago. He told me there aren't multiple companies interested and that it was difficult trying to get a fair valuation out of 1 single company. I have tried emailing, Calling and texting and no reply for over 1 month. His voicemail box is full. Either good news coming and he can't talk or company is in big trouble and doesn't want to talk.

he said we would be lucky to get 6 cents a share on a buyout. So I think licensing deal is more likely. Someone who will take equity and lend 15 million to finish Phase 3". RUN !!!

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities